Artrya Limited, a medical technology company, engages in the development and commercialization of artificial intelligence platform that detects, diagnoses, and address coronary artery disease in Australia. The company offers Salix, a suite ifcloud-based software that uses artificial intelligence to automate the detection of coronary artery disease from coronary computed tomography angiography scans to identify and manage patients at risk of a heart attack. Artrya Limited was incorporated in 2018 and is based in West Perth, Australia.